Vitamin D is usually synthesised in skin that is exposed to UV radiation, which has led to the term 'sunshine vitamin'^(^[@ref1]^)^. Traditionally, the primary role of vitamin D is related to calcium absorption and bone health. Children and adults with vitamin D deficiency have an increased risk of developing rickets or osteomalacia^(^[@ref2]^)^. Recently, a resurgence of childhood rickets has highlighted the need for adequate vitamin D status in many parts of the world^(^[@ref3]^--^[@ref5]^)^. Furthermore, mounting evidence from epidemiological studies indicates that vitamin D status is inversely associated with the risk of CVD, cancers and diabetes^(^[@ref1]^,^[@ref6]^)^, although there is some uncertainty about what defines an adequate vitamin D status^(^[@ref7]^)^.

Vitamin D deficiency is prevalent and is considered a serious issue throughout the world^(^[@ref8]^--^[@ref10]^)^, even in sunnier climates such as Australia and New Zealand^(^[@ref11]^)^. Recently, the Scientific Advisory Committee on Nutrition^(^[@ref7]^)^ reported that in the UK, 22--24 % of adults aged 19--64 years, and 17--24 % of those ≥65 years were vitamin D deficient (plasma 25-hydroxyvitamin D~3~ (25(OH)D~3~) \<25 nmol/l). There are several factors that have contributed to the low vitamin D status commonly seen today, such as lifestyle changes (increased indoor lifestyle, sun screens use) and human characteristics (e.g. ageing, clothing, increased obesity, low-fat diet trend)^(^[@ref12]^)^. Therefore, foods that contribute to vitamin D intake have become more important than before. However, there are only a few foods naturally rich in vitamin D, such as oily fish and egg yolks^(^[@ref13]^)^.

The aim of this review is first to critically evaluate the existing evidence on whether the vitamin D content of animal-derived foods can be increased by feeding cholecalciferol (vitamin D~3~) and/or calcifediol (25(OH)D~3~) supplements to laying hens, fish and cows. Second, the present review summaries evidence from the human randomised controlled trials (RCT), which include the effects of 25(OH)D~3~ supplementation on increasing serum/plasma 25(OH)D~3~ concentration.

Vitamin D absorption, synthesis and metabolism {#sec1}
==============================================

Generally, the term vitamin D refers to both vitamin D~2~ and vitamin D~3~. Vitamin D~2~ is produced by fungi, while vitamin D~3~ is produced by human subjects and animals^(^[@ref14]^)^. Human subjects usually synthesise vitamin D~3~ in the skin^(^[@ref15]^)^ where 7-dehydrocholesterol in the epidermis is converted to pre-vitamin D~3~ when skin is exposed to sunlight. Then, pre-vitamin D~3~ undergoes a temperature-dependent isomerisation to vitamin D~3~ over a period of approximately 3 d^(^[@ref6]^)^. Vitamin D (vitamin D~2~ or vitamin D~3~) can also be obtained from the diet^(^[@ref15]^)^ and it is absorbed with long-chain TAG in the small intestine^(^[@ref16]^)^. It is then incorporated into chylomicrons and transported in lymph to the blood and into the general circulation^(^[@ref17]^)^.

After entering the circulation, there are two hydroxylation reactions to convert vitamin D to the biologically active form^(^[@ref6]^)^. The first hydroxylation reaction is in the liver where vitamin D is hydroxylated to 25(OH)D by the vitamin D-25-hydroxylase enzyme. The second hydroxylation reaction is in the kidney where 25(OH)D is converted to 1,25(OH)~2~D by 25-hydroxyvitamin D-1*α*-hydroxylase^(^[@ref6]^)^, and the 1,25(OH)~2~D metabolite is the biologically active form of vitamin D^(^[@ref18]^)^.

Foods of animal origin as dietary sources of vitamin D {#sec2}
======================================================

Vitamin D content of vitamin D-enriched foods can differ considerably between food retailers. One US retail study analysed the vitamin D content of egg yolks collected from twelve individual retail supermarkets across the country and reported a broad range of vitamin D~3~ and 25(OH)D~3~ concentrations of 9·7--18 and 4·3--13·2 µg/kg, respectively^(^[@ref19]^)^. In addition, our recent UK retail study^(^[@ref20]^)^ showed vitamin D~3~ and 25(OH)D~3~ concentrations of eggs were significantly different depending on the egg production systems. Egg yolks produced by birds kept in indoor systems had much lower concentrations (40·2 ([se]{.smallcaps} 3·1) µg/kg) of vitamin D~3~ than the egg yolks produced from outdoor systems (57·2 ([se]{.smallcaps} 3·2) µg/kg), while 25(OH)D~3~ concentrations of the eggs were higher in organic eggs only. Similarly, the vitamin D contents of fish have been shown to vary according to the production systems. The study of Lu *et al.*^(^[@ref21]^)^ indicated the vitamin D~3~ content of wild salmon to be three times higher than that of farmed salmon; however, the 25(OH)D~3~ content of the salmon was not measured. In addition, other studies^(^[@ref22]^,^[@ref23]^)^ have shown the 25(OH)D~3~ content of several species of marine and freshwater fish to be \<0·02 µg/100 g. Therefore, foods generally regarded as rich sources of vitamin D may not be sustainable vitamin D contributors for the general population, due to variability in vitamin D content, which in turn may be influenced by production systems or different species (genotype). Furthermore, the National Diet and Nutrition Survey of the UK^(^[@ref24]^)^ reported that the average daily intake of vitamin D for adults was 3·1 µg for men and 2·6 µg for women, which is much lower than the UK vitamin D reference nutrition intake of 10 µg/d^(^[@ref7]^)^. Therefore, vitamin D-enriched or fortified foods are needed to ensure an adequate vitamin D intake for the general population.

Enrichment of animal-derived foods as dietary sources of vitamin D {#sec3}
==================================================================

Vitamin D-enriched eggs {#sec3-1}
-----------------------

In general, there are two main methods to enrich the vitamin D content of eggs: increased sunlight exposure and vitamin D supplementation of the birds' diet. Because hens can synthesise vitamin D from natural sunlight exposure, free-range egg production system may be an inexpensive way to increase their vitamin D content. A study by Kuhn *et al.* assigned laying hens to a free-range treatment or an indoor treatment for over 4 weeks and found that eggs from the free-range group, which were exposed to sunlight, had significantly higher vitamin D~3~ content (mean 14·3 µg/100 g DM) than eggs from the indoor group (mean 3·8 µg/100 g DM)^(^[@ref25]^)^. Furthermore, there are several studies which have shown that the vitamin D~3~ content of eggs can be enhanced by feeding vitamin D~3~ supplements to the hens ([Table 1](#tab01){ref-type="table"})^(^[@ref26]^--^[@ref32]^)^. The results of all studies revealed that egg yolk vitamin D~3~ concentration was efficiently increased by vitamin D~3~ dietary supplementation. The study of Yao *et al.* showed a linear dose--response relationship existed between vitamin D~3~ dietary supplementation and vitamin D~3~ concentrations of egg yolks^(^[@ref30]^)^. Moreover, as 25(OH)D~3~ is a metabolite of vitamin D~3~, the 25(OH)D~3~ content in eggs can also be enhanced by supplementing the birds' diet with vitamin D~3.~ However, the response in 25(OH)D~3~ content of egg yolk is much less than that of vitamin D~3.~ Browning and Cowieson^(^[@ref31]^)^ showed that a 4-fold increase in vitamin D~3~, and a 2-fold increase in 25(OH)D~3~ in egg yolk resulted from a 4-fold increase in the vitamin D~3~ in the diet (62·5--250 µg/kg). Similarly, evidence from another study showed that the vitamin D~3~ in egg yolk was increased approximately 7-fold as a result of feeding a diet with a 3·5-fold higher vitamin D~3~ content (from 62·4 to 216 µg/kg), while the corresponding increase in 25(OH)D~3~ content was only about 1·5-fold^(^[@ref26]^)^. Table 1.Summary of enrichment studies investigating the impact of adding vitamin D to the diet of laying hens on the vitamin D content of egg yolksReferencesVitamin D supplement (μg/kg)Feeding duration (weeks)Vitamin D concentration of egg yolk (μg/100 g)Vitamin D~3~25(OH)D~3~Vitamin D~3~25(OH)D~3~Mattila *et al.*^(^[@ref26]^)^26·6--61·40·562·4--63·50·9216·0--622·01·5Mattila *et al.*^(^[@ref27]^)^280·0--430·01·9Mattila *et al.*^(^[@ref28]^)^62·5--43·8--150·0--413·6--375·0--433·7--Browning and Cowieson^(^[@ref31]^)^62·5--96·51·6125·0--910·52·1250·0--926·23·0Yao *et al.*^(^[@ref30]^)^55·0--33·0--242·5--321·6--430·0--341·0--617·5--360·3--2555·0--3870·4--Browning and Cowieson^(^[@ref31]^)^62·5096·51·662·534·596·03·362·569·094·94·5125·00910·52·1125·034·597·44·5125·069·098·15·8250·00926·23·0250·034·5923·63·7250·069·0930·98·1Mattila *et al.*^(^[@ref29]^)^--55·06≤0·22·1--122·06≤0·24·3Duffy *et al.*^(^[@ref32]^)^37·5--41·0[\*](#tfn1_2){ref-type="table-fn"}1·9[\*](#tfn1_2){ref-type="table-fn"}75·0--42·0[\*](#tfn1_2){ref-type="table-fn"}1·9[\*](#tfn1_2){ref-type="table-fn"}37·537·541·3[\*](#tfn1_2){ref-type="table-fn"}3·6[\*](#tfn1_2){ref-type="table-fn"}75·040·7[\*](#tfn1_2){ref-type="table-fn"}4·4[\*](#tfn1_2){ref-type="table-fn"}[^1][^2]

There are only a few studies^(^[@ref29]^,^[@ref31]^,^[@ref32]^)^ examining the effect of feeding birds with diets supplemented with 25(OH)D~3.~ In the EU, 25(OH)D~3~ has only recently been authorised for addition to poultry diets, and the maximum content of the vitamin D~3~ and 25(OH)D~3~ combination for laying hens is 80 µg/kg^(^[@ref33]^,^[@ref34]^)^. It is of note that most of vitamin D supplementation studies^(^[@ref27]^--^[@ref31]^)^, summarised in [Table 1](#tab01){ref-type="table"}, had higher vitamin D doses than the EU diet limit^(^[@ref33]^)^, thus, the potential for increasing vitamin D in eggs by adding vitamin D to the diet of laying hens is limited by EU regulations. Browning and Cowieson^(^[@ref31]^)^ and Duffy *et al.*^(^[@ref32]^)^ both showed an addition of 25(OH)D~3~ to the vitamin D~3~ supplement resulted in the elevation of the 25(OH)D~3~ content of the egg yolk, but there was no significant increase in the vitamin D~3~ content of the egg yolk. Other studies investigated dietary supplementation with 25(OH)D~3~^(^[@ref29]^,^[@ref32]^)^, and showed that only egg yolk 25(OH)D~3~ was increased, but not vitamin D~3~. Therefore, we speculate that 25(OH)D~3~ in the diet can be absorbed directly by laying hens without transfer to vitamin D~3~ in the circulation.

Vitamin D-enriched fish {#sec3-2}
-----------------------

There are very few studies on enriching the vitamin D content of fish ([Table 2](#tab02){ref-type="table"})^(^[@ref35]^--^[@ref38]^)^. Mattila *et al.* fed rainbow trout with different doses of vitamin D~3~ supplements up to 539 µg/kg, but no significant differences in the vitamin D~3~ content of the fish fillet were observed^(^[@ref37]^)^. In contrast, the study of Horvli *et al.* with Atlantic salmon showed a dose--response relationship between the vitamin D~3~ in the diet up to 28·68 mg/kg and vitamin D~3~ in the fish meat^(^[@ref35]^)^. Similar high vitamin D~3~ supplementation doses were reported in another two studies^(^[@ref36]^,^[@ref38]^)^, which also showed that elevated vitamin D~3~ content of the fish liver or whole fish had been achieved by supplemental vitamin D~3~ in the diet. However, 25(OH)D~3~ contents of the enriched fish were not measured in these studies^(^[@ref35]^--^[@ref38]^)^, and the lack of evidence on the effects by feeding fish with 25(OH)D~3~ on the vitamin D content of the fish warrants further research. Again, supplement doses of the listed studies^(^[@ref35]^--^[@ref38]^)^ in [Table 2](#tab02){ref-type="table"} were over the EU diet limit for farmed fish of 75 µg/kg^(^[@ref33]^)^, which will limit application in the market. Table 2.Summary of enrichment studies investigating the impact of vitamin D supplemental fish feeding on vitamin D content of fishReferencesVitamin D~3~ supplement (μg/kg)Feeding duration (weeks)Vitamin D~3~ of fish (μg/100 g)Horvli *et al.*^(^[@ref35]^)^40111 (fillet)22101121 (fillet)28 68011210 (fillet)Vielma *et al.*^(^[@ref36]^)^62·5121 (liver)62501273 (liver)62 500126900 (liver)Mattila *et al.*^(^[@ref37]^)^89166--15 (fish fillet)174166--10 (fish fillet)539167--16 (fish fillet)Graff *et al.*^(^[@ref38]^)^2009≤25 (whole fish)[\*](#tfn2_1){ref-type="table-fn"}5000980 (whole fish)[\*](#tfn2_1){ref-type="table-fn"}57 0009650 (whole fish)[\*](#tfn2_1){ref-type="table-fn"}[^3]

Vitamin D-enriched milk {#sec3-3}
-----------------------

A few studies have investigated the longer term effect of supplemental vitamin D~3~ on the vitamin D content of the milk; the summary of these studies is presented in [Table 3](#tab03){ref-type="table"}^(^[@ref39]^--^[@ref42]^)^. Hollis *et al.* showed a 10-fold enhancement of vitamin D~3~ intake from 100 to 1000 µg/d resulted in a 7·5-fold increased vitamin D~3~ concentration of the milk and a 2-fold increase in 25(OH)D~3~^(^[@ref39]^)^. Moreover, McDermott *et al.* compared three different doses of vitamin D~3~ with a control diet, and showed an increased concentration of vitamin D~3~ and 25(OH)D~3~ in the milk^(^[@ref41]^)^. However, the relationship between increasing dietary vitamin D~3~ doses and milk vitamin D~3~ or 25(OH)D~3~ concentrations were not linear. Furthermore, the study of Weiss *et al.* investigated the effect of feeding 450 µg/d vitamin D~3~ to pre-calving cows for 13 d which resulted in concentrations of vitamin D~3~ and 25(OH)D~3~ in the milk ranging from 0·33--0·45 to 0·36--1·02 µg/l, respectively^(^[@ref42]^)^. In addition, the study included a diet treatment of 6 mg vitamin D~3~ with a cation--anion difference of −138 mEq/kg daily for 13 d; the concentrations of 25(OH)D~3~ in the milk were increased but the treatment effect disappeared after 28 d. Therefore, evidence from the limited number of studies^(^[@ref39]^--^[@ref42]^)^ demonstrated that milk vitamin D concentrations can be increased by feeding dairy cows with vitamin D supplements. However, it is of note that the highest milk vitamin D~3~ and 25(OH)D~3~ concentrations were 0·47 and 3·69 µg/l, respectively ([Table 3](#tab03){ref-type="table"}), which for one typical milk serving of 200 ml only contributes 0·09 and 0·74 µg vitamin D~3~ and 25(OH)D~3~, respectively, well below the current UK vitamin D reference nutrition intake of 10 µg/d^(^[@ref7]^)^. Furthermore, the doses of vitamin D in those studies^(^[@ref41]^,^[@ref42]^)^ were much higher than the maximum allowed vitamin D content in EU (0·01 mg/kg diet at 880 g DM/kg approximately equivalent to 2·27 mg/d)^(^[@ref34]^)^, which imposes an even greater restriction on the possibility of increasing vitamin D in milk by adding vitamin D supplements in the diet of dairy cows. Table 3.Summary of enrichment studies investigating the impact of vitamin D supplementation to the diet of dairy cows on vitamin D content of milkReferencesSupplements to diet (μg/d)Vitamin D concentration of milk (μg/l)Vitamin D~3~25(OH)D~3~Feeding durationVitamin D~3~25(OH)D~3~1,25(OH)~2~ D~3~Hollis *et al.*^(^[@ref39]^)^100--NA0·040·370·011000--NA0·320·680·004Reeve *et al.*^(^[@ref40]^)^375--30 d0·280·150·01Mcdermott *et al.*^(^[@ref41]^)^0--14 weeks0·080·250·10250--14 weeks0·200·430·031250--14 weeks0·150·750·136250--14 weeks0·330·930·10Weiss *et al.*^(^[@ref42]^)^450--13 d before calving0·33--0·470·36--1·02----DCAD + 600013 d before calving--0·61--3·69--[^4]

Evidence from human dietary intervention studies with vitamin D-enriched animal-derived foods {#sec4}
=============================================================================================

Despite numerous animal-based vitamin D-enrichment studies on vitamin D in eggs, fish and milk, there are few RCT on the effect of consuming vitamin D-enriched foods on the vitamin D status of the consumer. To our knowledge, only one recent study has investigated the weekly effect of consuming seven vitamin D~3~ or seven 25(OH)D~3~-enriched eggs on vitamin D status compared with commercial eggs of ≤2 egg/week^(^[@ref43]^)^. After 8 weeks follow-up in winter, the results showed that while the serum 25(OH)D of the subjects who consumed commercial eggs decreased from a baseline of 41 ([sd]{.smallcaps} 14·1) nmol/l to 35 ([sd]{.smallcaps} 11·4) nmol/l, the serum 25(OH)D of subjects who consumed vitamin D~3~-enriched eggs or 25(OH)D~3~-enriched eggs was maintained. The serum 25(OH) D concentrations of subjects who consumed vitamin D~3~- or 25(OH)D~3~-enriched eggs were 50 ([sd]{.smallcaps} 21·4) nmol/l and 49 ([sd]{.smallcaps} 16·5) nmol/l, respectively. However, there was no significant difference between vitamin D~3~- and 25(OH)D~3~-enriched egg consumption on serum 25(OH)D concentrations.

Although there are a limited number of human dietary intervention studies on vitamin D-enriched foods, the study of Mattila *et al.*^(^[@ref29]^)^ demonstrated that the effect of foods enriched with either vitamin D~3~ or 25(OH)D~3~ on human vitamin D status depended on their relative effectiveness of raising serum or plasma 25(OH)D concentrations. A previous study^(^[@ref44]^)^ indicated that there was no consensus on the relative effectiveness of 25(OH)D~3~ compared with vitamin D~3~ for raising human serum or plasma 25(OH)D~3~ concentrations. Furthermore, UK food composition tables^(^[@ref45]^)^ indicate that there is no certainty on the relative potency of 25(OH)D~3~ compared with vitamin D~3~, although it was assumed that 25(OH)D~3~ had a potency of five times that of vitamin D~3~ for calculating the total vitamin D of foods^(^[@ref45]^)^.

Human intervention studies on the relative effects of calcifediol and cholecalciferol supplementation on vitamin D status {#sec5}
=========================================================================================================================

Heterogeneity of intervention studies {#sec5-1}
-------------------------------------

Eleven RCT that investigated the effects of 25(OH)D~3~ relative to vitamin D~3~ were identified^(^[@ref46]^--^[@ref56]^)^ ([Table 4](#tab04){ref-type="table"}). Nine studies administered 25(OH)D~3~ supplementation only, except two studies which provided a combination supplement of 25(OH)D~3~ and calcium^(^[@ref46]^,^[@ref49]^)^. Five of the eleven studies^(^[@ref47]^,^[@ref49]^--^[@ref52]^)^ supplemented 25(OH)D~3~ to generally healthy subjects, whereas the other six studies^(^[@ref46]^,^[@ref48]^,^[@ref53]^--^[@ref56]^)^ supplemented 25(OH)D~3~ to clinical patients. Most studies reported the serum or plasma 25(OH)D concentration at both the beginning and end of the treatment, except one study^(^[@ref55]^)^, which only reported the 25(OH)D concentration at the end of the treatment. In terms of the vitamin D status measurement, most studies measured total 25(OH)D concentration, except two studies^(^[@ref49]^,^[@ref52]^)^, which measured 25(OH)D~3~. For the characteristics of the investigated subjects, five studies included both men and women^(^[@ref46]^,^[@ref48]^,^[@ref51]^,^[@ref53]^,^[@ref55]^)^, while the other studies only included men or women. In addition, most studies reported the age and BMI of the subjects, except two studies^(^[@ref46]^,^[@ref48]^)^ that did not report the BMI range. Table 4.Summary of study details and serum 25, hydroxyvitamin D (25(OH)D) concentration in long-term randomised controlled trials with calcifediol (25 hydroxyvitamin D~3~ (25(OH)D~3~)) supplementation in adults (order by year)ReferencesSubjects characteristics (trail time during the year, subjects (sex), age, BMI)25(OH)D~3~ supplementation groupControl group (if available)Duration25(OH)D~3~ treatment*n*Baseline 25(OH)D (nmol/l)Endpoint 25(OH)D (nmol/l)DurationVitamin D~3~ treatment*n*Baseline 25(OH)D (nmol/l)Endpoint 25(OH)D (nmol/l)Hahn *et al.*^(^[@ref46]^)^Whole year, patients (women and men) with glucocorticoid-induced osteopenia\
46 years, BMI (NA[\*](#tfn4_1){ref-type="table-fn"})18 months40 µg/d + 500 mg calcium/d939205Barger-Lux *et al.*^(^[@ref47]^)^January--April, men\
28 years, 26 kg/m^2^4 weeks10 µg/d7671078 weeks25 µg/d1367964 weeks20 µg/d6671438 weeks250 µg/d10672134 weeks50 µg/d4672738 weeks1250 µg/d1467710Jean *et al.*^(^[@ref48]^)^March--September, haemodialysis patients (women and men) 67 years, BMI (NA)6 months16 µg /d14930126Cavalli *et al.*[^§^](#tfn4_4){ref-type="table-fn"}^(^[@ref49]^)^April--July, postmenopausal women\
65--75 years, 25 kg/m^2^12 weeks125 µg/week + \
500 mg calcium/d25507612 weeks250 µg/month + \
500 mg calcium/d28517012 weeks500 µg/month + \
500 mg calcium/d275277Russo *et al.*^(^[@ref50]^)^January--April, women (7 premenopausal and 11 postmenopausal), 24--72 years, 24 kg/m^2^16 weeks500 µg/month1845105[^†^](#tfn4_2){ref-type="table-fn"}Cashman *et al.*^(^[@ref51]^)^January--April, women and men, 57 years, 29 kg/m^2^10 weeks20 µg/d123813510 weeks20 µg/d135069Jetter *et al.*[^‡^](#tfn4_3){ref-type="table-fn"}[^§^](#tfn4_4){ref-type="table-fn"}^(^[@ref52]^)^January--July, postmenopausal women 50--70 years, 18--29 kg/m^2^16 weeks20 µg/d53117316 weeks20 µg/d53577Catalano *et al.*^(^[@ref54]^)^September--March, osteopenic and dyslipidaemic postmenopausal women\
59 years, 27 kg/m^2^24 weeks140 µg once weekly295612624 weeks140 µg once weekly285161Banon *et al.*^(^[@ref53]^)^Whole year, patients (women and men) had HIV-infected, 44 years, 15--44 kg/m^2^Summer400 µg once/month1233786SummerNA2425399Fall400 µg once/month1233769FallNA2425384Winter400 µg once/month1233745WinterNA2425355Spring400 µg once/month1233757SpringNA2425378Ortego-Jurado *et al.*^(^[@ref55]^)^Whole year, patients (women and men) had autoimmune diseases, undergoing glucocorticoids therapy, 56 years, 28 kg/m^2^Spring--summer8·85 µg/d49NA84Spring--summer20 µg/d86NA71Fall--winter8·85 µg/d49NA89Fall--winter20 µg/d86NA61Navarro-Valverde *et al.*^(^[@ref56]^)^Whole year, postmenopausal osteoporotic women, 67 years, 26 kg/m^2^6 months20 µg/d10371616 months20 µg/d10418012 months20 µg/d103718812 months20 µg/d1041866 months266 µg once/week103821412 months266 µg once/week10382336 months266 µg once/2 weeks104016512 months266 µg once/2 weeks1040211[^5][^6][^7][^8]

Acute pharmacokinetic action of cholecalciferol and calcifediol {#sec5-2}
---------------------------------------------------------------

An early study provided meals with single doses of 25(OH)D~3~ of 1·5, 5 or 10 µg/kg body weight to generally healthy subjects and showed that the peak serum 25(OH)D~3~ concentration was reached within 4--8 h after ingestion^(^[@ref57]^)^. A later study by Jetter *et al.* compared the pharmacokinetic absorption of vitamin D~3~ and 25(OH)D~3~ by providing a single dose of 20 µg vitamin D~3~ or 20 µg 25(OH)D~3~ to postmenopausal women^(^[@ref52]^)^. The time to reach maximum plasma 25(OH)D~3~ concentration was 22 and 11 h for vitamin D~3~ and 25(OH)D~3~, respectively. In addition, the peak concentration of plasma 25(OH)D~3~ (44 nmol/l) from 25(OH)D~3~ supplementation was higher than vitamin D~3~ supplementation (35 nmol/l), although they were not significantly different. This study further compared the effect of a higher single dose of 140 µg vitamin D~3~ and 140 µg 25(OH)D~3~ with the time to reach peak plasma 25(OH)D~3~ being 21 and 4·8 h for vitamin D~3~ and 25(OH)D~3~ supplementation, respectively^(^[@ref52]^)^. In addition, the maximum plasma concentration of 25(OH)D~3~ for 25(OH)D~3~ treatment (100 nmol/l) was significantly higher than for vitamin D~3~ treatment (44 nmol/l). These results suggest that 25(OH)D~3~ was absorbed more quickly than vitamin D~3~ possibly because 25(OH)D~3~ has higher solubility in aqueous media than vitamin D~3~ due to its more polar chemical structure^(^[@ref58]^)^. Furthermore, as this metabolite of vitamin D~3~ is produced in the liver, the hepatic metabolism of vitamin D~3~ to 25(OH)D~3~ is circumvented and consequently the conversion from vitamin D~3~ to 25(OH)D~3~ would be negligible^(^[@ref59]^)^. In patients with liver disease who had an impaired ability to synthesise 25(OH)D~3~ from vitamin D~3~^(^[@ref60]^)^, the study of Sitrin and Bengoa^(^[@ref61]^)^ verified that 25(OH)D~3~ could be absorbed more efficiently than vitamin D~3~ after oral supplementation. Therefore, supplementation with 25(OH)D~3~ is not only more efficient at increasing vitamin D status in generally healthy people, but may also have a specific role in tackling lower vitamin D status in patients who are suffering from liver diseases.

Chronic effects and relative effectiveness of cholecalciferol and calcifediol treatments {#sec5-3}
----------------------------------------------------------------------------------------

Regarding the expected higher biological effect of 25(OH)D~3~ in raising serum or plasma 25(OH)D level after long-term administration, several studies have confirmed that oral consumption of 25(OH)D~3~ is highly effective in raising serum or plasma 25(OH)D level ([Table 4](#tab04){ref-type="table"})^(^[@ref46]^--^[@ref56]^)^. However, the majority of the evidence in support of a higher impact of 25(OH)D~3~ supplementation compared with vitamin D~3~ on serum or plasma 25(OH)D~3~ level is from only four studies^(^[@ref51]^,^[@ref52]^,^[@ref54]^,^[@ref56]^)^ where both 25(OH)D~3~ and vitamin D~3~ treatments were included in the same study ([Table 5](#tab05){ref-type="table"}). The study of Barger-Lux *et al.*^(^[@ref47]^)^ provided three different doses of vitamin D~3~ (25, 250, 1250 µg/d) or 25(OH)D~3~ (10, 20, 50 µg/d) to the participants for 8 and 4 weeks, respectively. However, the effects of 25(OH)D~3~ and vitamin D~3~ treatments were not directly comparable as the interventions were not at the same dose or treatment time. Thus, the study of Barger-Lux *et al.*^(^[@ref47]^)^ was excluded from the relative effectiveness analysis. In order to compare the relative effectiveness of 25(OH)D~3~ and vitamin D~3~ supplementation on raising serum or plasma 25(OH)D concentrations, a dose--response factor was calculated for each μg of orally consumed 25(OH)D~3~ or vitamin D~3~ in four studies^(^[@ref51]^,^[@ref52]^,^[@ref54]^,^[@ref56]^)^. The dose--response factors of 25(OH)D~3~ and vitamin D~3~ were calculated by using endpoint 25(OH)D concentration minus baseline 25(OH)D concentration, divided by the dose of the supplementation (dose--response factor = Δ serum/plasma (mmol/l)/dose (μg)). Then, the relative effectiveness of 25(OH)D~3~ to vitamin D~3~ was calculated by dividing the dose--response factor of 25(OH)D~3~ by that of vitamin D~3~. Table 5.Summary of randomised controlled trials with both calcifediol (25 hydroxyvitamin D~3~ (25(OH)D~3~)) and vitamin D~3~ in adults to calculate the relative effectiveness of 25(OH)D~3~ and vitamin D~3~ supplementation in raising serum 25, hydroxyvitamin D (25(OH)D) levelReferencesTreatment (dose, duration)Serum 25(OH)D raising (nmol/l) per 1 μg[\*](#tfn5_1){ref-type="table-fn"}Relative effectiveness[^†^](#tfn5_2){ref-type="table-fn"}Cashman *et al.*^(^[@ref51]^)^20 µg 25(OH)D~3~/d × 10 weeks4·82^a^4·9920 µg vitamin D~3~/d × 10 weeks0·97^b^Jetter *et al.*^(^[@ref52]^)^20 µg 25(OH)D~3~/d × 15 weeks7·12^a^3·4020 µg vitamin D~3~/d × 15 weeks2·51^b^Catalano *et al.*^(^[@ref54]^)^140 µg 25(OH)D~3~/week × 24 weeks0·50^a^7·14140 µg vitamin D~3~/week × 24 weeks0·07^b^Navarro-Valverde *et al.*^(^[@ref56]^)^20 µg 25(OH)D~3~/d × 6 months6·19^a^3·1320 µg vitamin D~3~/d × 6 months1·98^b^20 µg 25(OH)D~3~/d × 12 months7·54^a^3·2920 µg vitamin D~3~/d × 12 months2·29^b^[^9][^10]

The highest relative effectiveness was found in the study by Catalano *et al.*^(^[@ref54]^)^. Weekly treatment of 140 µg 25(OH)D~3~ or 140 µg vitamin D~3~ supplements was provided to osteopenic and dyslipidaemic postmenopausal women for 24 weeks. Supplementation with 25(OH)D~3~ raised serum 25(OH)D from a baseline of 56--126 nmol/l, while vitamin D~3~ treatment increased serum 25(OH)D to a lower extent, from baseline 51 to 61 nmol/l. Thus, the relative effectiveness factor derived from this study was 7·14, i.e. dietary 25(OH)D~3~ was 7·14 times more effective at increasing serum 25(OH)D than dietary vitamin D~3~.

Vitamin D dietary recommendations are generally between 10 and 20 µg/d^(^[@ref10]^)^, yet, there are few studies which have compared the effectiveness of dietary 25(OH)D~3~ and vitamin D~3~ using doses of 20 µg in their treatments. Cashman *et al.*^(^[@ref51]^)^ provided daily supplements of 20 µg vitamin D~3~ or 20 µg 25(OH)D~3~ to adult men and women with a mean age of 57 years and with baseline serum 25(OH)D of 28·9 nmol/l during winter. After 10 weeks of supplementation, the subjects' serum 25(OH)D increased to 135 and 69 nmol/l for the 25(OH)D~3~ and vitamin D~3~ treatments, respectively. A relative effectiveness factor of 4·99 was calculated representing the relative effectiveness of each μg of dietary 25(OH)D~3~ relative to dietary vitamin D~3~ for raising serum 25(OH)D concentration. However, lower relative effectiveness factors were achieved in other studies using the same dose of 20 µg vitamin D~3~ and 25(OH)D~3~. Jetter *et al.* supplemented healthy postmenopausal women with 20 µg 25(OH)D~3~ or 20 µg vitamin D~3~ for 16 weeks during the winter^(^[@ref52]^)^. They found that for the 25(OH)D~3~ treatment, plasma 25(OH)D~3~ increased to 173 nmol/l from a baseline of 31 nmol/l, whereas for the vitamin D~3~ treatment, plasma 25(OH)D~3~ increased to 77 nmol/l from a baseline level of 35 nmol/l. The relative effectiveness factor of each μg of 25(OH)D~3~ was 3·40 compared with vitamin D~3~ in raising plasma 25(OH)D~3~ level. A similar low relative effectiveness factor was found in another study where post-menopausal osteoporotic women were given either 20 µg vitamin D~3~ or 20 µg 25(OH)D~3~ over 6 or 12 months^(^[@ref56]^)^. The serum concentration of 25(OH)D for the 25(OH)D~3~ treatment reached 161 and 188 nmol/l from a baseline of 37 nmol/l after 6 or 12 months administration, respectively, while the comparable values for the vitamin D~3~ treatment were an increase to 80 and 86 nmol/l from a baseline of 41 nmol/l. So the relative effectiveness factor of 25(OH)D~3~ relative to vitamin D~3~ treatment at 6 and 12 months were 3·13 or 3·29, respectively.

In summary, of the studies reviewed, the relative effectiveness of 25(OH)D~3~ to vitamin D~3~ for raising vitamin D status ([Table 5](#tab05){ref-type="table"}), ranged from 3·13 to 7·14. Previous studies have demonstrated that the season may have influences on vitamin D status^(^[@ref13]^,^[@ref14]^)^. There were two studies conducted during the winter which may have minimised any confounding influence of cutaneous vitamin D synthesis from UV radiation ^(^[@ref47]^,^[@ref51]^)^. Other studies have longer intervention periods of 6 months or more, which could not have avoided some cutaneous synthesis. Furthermore, baseline status may be another factor that influences the relative effectiveness factor. The study of Catalano *et al.* had the highest factor of 7·14 in the present review, and the baseline concentration of 25(OH)D of the study participants was higher (\>50 nmol/l) than the others^(^[@ref54]^)^. Therefore, the different relative effectiveness seen in different studies may be due to the different characteristics or genotypes of the subjects, or different study designs.

Overall, evidence suggests that dietary 25(OH)D~3~ can more effectively increase serum 25(OH)D concentrations than vitamin D~3~ and may also be absorbed faster reaching a serum or plasma 25(OH)D plateau earlier than vitamin D~3~ supplementation. Furthermore, supplementation with 25(OH)D~3~ may also have more benefits to human health compared with vitamin D~3~ in a general healthy population. Bischoff-Ferrari *et al.* reported that 20 µg 25(OH)D~3~ supplementation over 4 months led to a 5·7 mmHg decrease in systolic blood pressure and improvements in several markers of innate immunity in healthy postmenopausal women^(^[@ref62]^)^.

For patients with different diseases and receiving long-term medication, studies^(^[@ref63]^--^[@ref65]^)^ showed that several drugs (e.g. antiepileptic agents, glucocorticoids, antiretroviral or anti-oestrogen drugs) interfered with vitamin D metabolism, which resulted in patients being more likely to have low vitamin D status. Thus, it is not only important to increase vitamin D status in the generally healthy population but also in patients with specific illnesses and receiving certain medication. Therefore, the studies using 25(OH)D~3~ treatments in patients were also summarised in [Table 4](#tab04){ref-type="table"}^(^[@ref46]^,^[@ref48]^,^[@ref53]^--^[@ref56]^)^, and those studies consistently reported that chronic 25(OH)D~3~ supplementation effectively increased serum 25(OH)D concentrations. For example, Ortego-Jurado *et al.* showed a lower daily dose of 8·85 µg 25(OH)D~3~ to be more effective than a 20 µg dose of vitamin D~3~ for increasing vitamin D status in patients with autoimmune disease who were treated with a low dose of glucocorticoids throughout the year^(^[@ref55]^)^. Similarly, the study of Banon *et al.* showed that a monthly dose of 400 µg 25(OH)D~3~ was safe and effective at improving vitamin D status of HIV-infected patients throughout the year^(^[@ref53]^)^.

Furthermore, supplementation with 25(OH)D~3~ may have additional benefits on patients' health. Previously, 25(OH)D~3~ was recommended for patients with kidney disease since 25(OH)D~3~ has a direct action on bone metabolism^(^[@ref66]^)^. Hahn *et al.* provided a daily 40 µg 25(OH)D~3~ and 500 mg calcium supplement to patients who had glucocorticoid-induced osteopenia for 18 months^(^[@ref46]^)^. The treatment markedly increased vitamin D status from 39 to 205 nmol/l. In addition, this study showed that the 25(OH)D~3~ treatment improved mineral and bone metabolism. Jean *et al.* also offered haemodialysis patients who suffered from vitamin D deficiency with a daily dose of 16 µg 25(OH)D~3~ for 6 months; vitamin D status reached 126 nmol/l from 30 nmol/l, at the same time 25(OH)D~3~ supplementation corrected the excess bone turnover^(^[@ref48]^)^. Similarly, a study by Catalano *et al.*^(^[@ref54]^)^ provided 140 µg 25(OH)D~3~ supplements for 24 weeks to osteopenic and dyslipidaemic postmenopausal women, and results showed that 25(OH)D~3~ improved plasma lipid levels (increased HDL-cholesterol (*P* = 0·02) and decreased LDL-cholesterol (*P* = 0·02)) in osteopenic and dyslipidaemic postmenopausal women when added to an ongoing atorvastatin treatment.

As an alternative to vitamin D-enriched foods, vitamin D fortification of foods may also be an option for tackling vitamin D deficiency throughout the world. In general, fortification of foods refers to mandatory and voluntary fortification. The contribution of vitamin D-fortified foods to vitamin D intake by the public varies considerably between countries as there are different food standard policies^(^[@ref10]^)^, and in practice, vitamin D~2~ or vitamin D~3~ are used for fortification. Evidence from one previous meta-analysis of RCT showed that vitamin D~3~ supplementation is more effective at raising vitamin D status than vitamin D~2~^(^[@ref67]^)^. However, a further comprehensive systematic review and meta-analysis of thirty-three RCT^(^[@ref68]^)^ showed that the effect of vitamin D~3~ supplement on serum 25(OH)D~3~ response was limited by the supplemental dose, duration, age of subjects and baseline level. In addition, the meta-analysis showed a greater serum or plasma 25(OH)D increase when the intervention study used a dose of 20 µg/d vitamin D~3~ or even higher, with subjects aged \>80 years and an administration period of at least 6--12 months or subjects had lower baseline 25(OH)D status (\<50 nmol/l) than subjects aged \<80 years, administration period \<6 months or subjects had higher baseline 25(OH)D status (≥50 nmol/l)^(^[@ref68]^)^. Therefore, better strategies are needed to raise vitamin D status of the public throughout life, and 25(OH)D~3~-fortified foods warrant further research.

Conclusions {#sec6}
===========

Vitamin D insufficiency has become a world problem, especially where sunlight exposure is limited by geographic reasons (latitude), personal characteristics (skin pigmentation, ageing) or behaviour (sunscreen use, cultural reasons). However, there are a few natural foods rich in vitamin D. Thus, vitamin D-enriched foods produced through a food chain approach such as feeding animals vitamin D supplements or vitamin D-fortified foods are needed to guarantee an adequate dietary intake of vitamin D by the general population.

The present review summarised the available and limited number of RCT investigating the effect of 25(OH)D~3~ supplementation on serum or plasma 25(OH)D concentration. We concluded that it is difficult to get consensus on the effectiveness of 25(OH)D~3~ supplementation relative to vitamin D~3~ for raising vitamin D status, due to various influencing factors such as different person characteristics (age, BMI), baseline vitamin D status and time of the year. However, it is unquestionable that 25(OH)D~3~ supplementation is more efficient at raising serum 25(OH)D concentrations and also appears to be absorbed faster by than the same dose of vitamin D~3~. Second, by reviewing available evidence on vitamin D-enriched eggs, fish or milk, it is practical and possible to increase the vitamin D content of eggs, fish or milk by addition of vitamin D supplements to the diet of poultry, fish or dairy cows. However, the limitations of adding vitamin D to animal feed should be considered in future enrichment studies. Furthermore, there are a few RCT investigating the impact of these vitamin D-enriched foods on improving vitamin D status. Therefore, 25(OH)D~3~-enriched or fortified foods should be further explored in the future, and additional RCT should be conducted to investigate the effect of 25(OH)D~3~-enriched or fortified foods on vitamin D status of the general population and patients with long-term health conditions.
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[^1]: 25(OH)D~3~, 25-hydroxyvitamin D~3~.

[^2]: Vitamin D content per egg.

[^3]: Estimated from graph.

[^4]: 25(OH)D~3~, 25-hydroxyvitamin D~3~; 1,25(OH)~2~D~3~, 1,25 dihydroxyvitamin D~3~; DCAD, dietary cation--anion difference of −138 mEq/kg.

[^5]: NA, not available.

[^6]: Estimated from graph.

[^7]: Same study of (Jetter *et al.*^(^[@ref52]^)^) and (Bischoff-Ferrari *et al.*^(^[@ref62]^)^).

[^8]: Study has measured vitamin D status as 25(OH)D~3~.

[^9]: Dose--response factor = Δ serum/plasma (mmol/l)/dose (μg).

[^10]: Relative effectiveness = a/b within same study.
